Detalhe da pesquisa
1.
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Lancet
; 399(10323): 461-472, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065705
2.
Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
J Infect Dis
; 217(4): 567-571, 2018 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29325161
3.
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Vaccine
; 41(11): 1875-1884, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36781334
4.
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Hum Vaccin Immunother
; 19(1): 2206359, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226504
5.
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
Lancet Reg Health West Pac
; 24: 100484, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35664443
6.
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
NPJ Vaccines
; 7(1): 12, 2022 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35087084
7.
Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial.
Vaccine X
; 6: 100074, 2020 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33005887
8.
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report.
Vaccine
; 38(28): 4476-4483, 2020 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31585725
9.
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
EClinicalMedicine
; 27: 100540, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150320
10.
The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Pediatr Infect Dis J
; 28(4 Suppl): S89-96, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19325451
11.
Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study.
Int J Infect Dis
; 46: 71-8, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26923083
12.
Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.
Vaccine
; 32(7): 888-94, 2014 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24176498
13.
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Lancet Infect Dis
; 14(2): 119-29, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24290843